Zacks: Brokerages Anticipate Assembly Biosciences Inc (NASDAQ:ASMB) Will Announce Quarterly Sales of $12.54 Million

Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report sales of $12.54 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Assembly Biosciences’ earnings. The highest sales estimate is $36.04 million and the lowest is $4.00 million. Assembly Biosciences posted sales of $3.08 million in the same quarter last year, which suggests a positive year-over-year growth rate of 307.1%. The business is expected to issue its next quarterly earnings report on Monday, August 3rd.

According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next year, analysts anticipate that the firm will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.22. The company had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%.

A number of research firms recently commented on ASMB. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, April 8th. Mizuho reissued a “buy” rating and set a $30.00 price target on shares of Assembly Biosciences in a research report on Friday, May 8th. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a research report on Thursday. Finally, BidaskClub raised shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $39.75.

In other news, EVP Richard James Colonno sold 7,812 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $15.04, for a total transaction of $117,492.48. Following the completion of the transaction, the executive vice president now directly owns 144,821 shares of the company’s stock, valued at approximately $2,178,107.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.42% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC grew its stake in Assembly Biosciences by 301.5% in the 4th quarter. EcoR1 Capital LLC now owns 2,388,268 shares of the biopharmaceutical company’s stock valued at $48,864,000 after acquiring an additional 1,793,368 shares during the period. BlackRock Inc. grew its stake in Assembly Biosciences by 15.6% in the 1st quarter. BlackRock Inc. now owns 2,297,866 shares of the biopharmaceutical company’s stock valued at $34,079,000 after acquiring an additional 310,648 shares during the period. Victory Capital Management Inc. grew its stake in Assembly Biosciences by 30,224.0% in the 4th quarter. Victory Capital Management Inc. now owns 1,325,460 shares of the biopharmaceutical company’s stock valued at $27,119,000 after acquiring an additional 1,321,089 shares during the period. Franklin Resources Inc. acquired a new stake in Assembly Biosciences in the 4th quarter valued at $14,829,000. Finally, FMR LLC grew its stake in Assembly Biosciences by 328.7% in the 4th quarter. FMR LLC now owns 717,217 shares of the biopharmaceutical company’s stock valued at $14,675,000 after acquiring an additional 549,924 shares during the period. 88.34% of the stock is currently owned by hedge funds and other institutional investors.

ASMB stock traded up $0.65 during trading on Friday, reaching $23.81. The company had a trading volume of 166,900 shares, compared to its average volume of 261,602. The firm has a 50-day simple moving average of $20.86 and a 200-day simple moving average of $18.82. The company has a market cap of $757.85 million, a price-to-earnings ratio of -6.94 and a beta of 1.26. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.14 and a current ratio of 12.14. Assembly Biosciences has a twelve month low of $8.13 and a twelve month high of $25.07.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Read More: What causes a recession?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.